Form 4: RAPT Therapeutics Director Acquires Stock Options
SEC Form 4
Lori Lyons-Williams, a director of RAPT Therapeutics, acquired stock options for 36,490 shares of common stock on May 22, 2024.
Summary
- Lori Lyons-Williams, a director at RAPT Therapeutics, acquired stock options to purchase 36,490 shares of common stock.
- The transaction occurred on May 22, 2024.
- The exercise price of the options is $4.63 per share.
- The options vest in 12 equal monthly installments starting from the grant date of May 22, 2024.
- The options expire on May 21, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing indicating a director's acquisition of stock options, which is neither overtly positive nor negative.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of compensation.
Stakeholder Impact
- The acquisition of stock options by a director may have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/22/2024 | Date of transaction and grant of stock options. |
| 05/22/2024 | Vesting start date. |
| 05/21/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.